Liproxstatin-1 HCl: Potent Ferroptosis Inhibitor for Acute Renal Failure Research

Executive Summary: Liproxstatin-1 HCl (CAS 950455-15-9) is a nanomolar-potency, selective inhibitor of ferroptotic cell death, acting by suppressing iron-dependent lipid peroxidation (Wen et al., 2023, DOI). It does not inhibit apoptosis or necroptosis, making it an ideal mechanistic probe. In cellular and animal models, Liproxstatin-1 HCl rescues cells from ferroptosis induced by RSL3, erastin, and L-buthionine sulphoximine. In vivo, it reduces tubular cell death and extends survival after acute renal failure or hepatic ischemia/reperfusion injury. APExBIO provides Liproxstatin-1 HCl as a hydrochloride salt for research use only (product page).

Biological Rationale

Ferroptosis is an iron-dependent, regulated form of cell death characterized by accumulation of lipid peroxides in cellular membranes. This process is distinct from apoptosis, necroptosis, and other forms of regulated cell death (Wen et al., 2023). Glutathione peroxidase 4 (GPX4) is a key repressor of ferroptosis, catalyzing the reduction of lipid hydroperoxides to non-toxic lipid alcohols using glutathione as a cofactor. Genetic or pharmacological inhibition of GPX4 induces ferroptosis, which is implicated in acute renal failure, ischemia/reperfusion injury, and several neurodegenerative diseases. The biological rationale for targeting ferroptosis is to prevent or minimize tissue damage in these pathological states, providing a tractable target for chemical intervention. Liproxstatin-1 HCl offers a selective approach to dissecting these pathways, as it spares cells dying via apoptosis or oxidative necrosis (Wen et al., 2023).

Mechanism of Action of Liproxstatin-1 HCl

Liproxstatin-1 HCl is a synthetic, lipophilic antioxidant that directly inhibits lipid peroxidation, thereby blocking the execution phase of ferroptosis. It achieves this by scavenging lipid radicals and preserving membrane integrity. The compound demonstrates an IC₅₀ of 22 nM for inhibition of ferroptosis in cellular models, including GPX4-deficient and RAS-transformed cell lines, as well as primary human renal proximal tubule epithelial cells (HRPTEpiCs) (Wen et al., 2023). Liproxstatin-1 HCl does not rescue cell death induced by classic apoptosis triggers (e.g., staurosporine) or by general oxidative stress (e.g., H₂O₂), confirming its selectivity as a ferroptosis inhibitor. Mechanistically, it acts downstream of glutathione depletion and GPX4 inactivation, suggesting a role in direct interruption of lipid peroxidation propagation chains (Wen et al., 2023).

Evidence & Benchmarks

• Liproxstatin-1 HCl inhibits ferroptosis with an IC₅₀ of 22 nM in GPX4-deficient cell lines (Wen et al., 2023, DOI).
• Prevents ferroptosis in primary human renal proximal tubule epithelial cells (HRPTEpiCs) exposed to RSL3, L-buthionine sulphoximine, or erastin (Wen et al., 2023, DOI).
• Does not rescue cell death from apoptosis inducers (e.g., staurosporine) or H₂O₂-mediated necrosis, confirming pathway selectivity (Wen et al., 2023, DOI).
• In vivo, reduces TUNEL-positive cell death and extends survival in mouse models of acute renal failure and hepatic ischemia/reperfusion injury (Wen et al., 2023, DOI).
• Supplied as a hydrochloride salt (N-(3-chlorobenzyl)-4'H-spiro[piperidine-4,3'-quinoxalin]-2'-amine hydrochloride) with water solubility ≥18.85 mg/mL and DMSO solubility ≥47.6 mg/mL (APExBIO).

This article extends the mechanistic insights presented in Mechanistic Mastery and Strategic Leverage by focusing on Liproxstatin-1 HCl's quantitative benchmarks and protocol integration in acute renal failure models. For advanced troubleshooting and translational applications, see this practical guide, which is complemented here by updated in vivo validation data.

Applications, Limits & Misconceptions

Liproxstatin-1 HCl is widely used in research to dissect ferroptosis in cellular and animal models, especially in acute renal failure and hepatic ischemia/reperfusion injury workflows. Its nanomolar potency and high selectivity make it the compound of choice for distinguishing ferroptotic from apoptotic or necroptotic cell death.

Common Pitfalls or Misconceptions

• Not a pan-cell death inhibitor: Liproxstatin-1 HCl does not inhibit apoptosis, necroptosis, or general oxidative necrosis (DOI).
• Insoluble in ethanol: The compound is not soluble in ethanol; use water or DMSO for stock solutions (APExBIO).
• Storage requirements: Stock solutions in DMSO should be stored at -20°C for optimal stability (APExBIO).
• Not for diagnostic or medical use: Liproxstatin-1 HCl is provided strictly for scientific research; clinical or diagnostic applications are not supported (APExBIO).
• Pathway specificity: Inhibition is limited to iron-dependent lipid peroxidation-mediated cell death pathways (DOI).

Workflow Integration & Parameters

Liproxstatin-1 HCl (SKU B8221, by APExBIO) is supplied as a solid hydrochloride salt. For routine cell-based assays, prepare a stock solution in DMSO (≥47.6 mg/mL), store at -20°C, and dilute into cell culture medium at final concentrations ranging from 10–100 nM. For in vivo research, dosing should reflect published protocols, with consideration of pharmacokinetics and solubility. Sonication and gentle warming can enhance dissolution at higher concentrations. The compound is water-soluble (≥18.85 mg/mL) but not ethanol-soluble. Always include appropriate vehicle and ferroptosis-inducer controls for assay validation.

Refer to the Liproxstatin-1 HCl product page for detailed handling and storage instructions. For protocol optimization and troubleshooting, see the protocol-focused article here; this article adds updated benchmarking data and clarifies compound use in translational workflows.

Conclusion & Outlook

Liproxstatin-1 HCl is established as a gold-standard tool for ferroptosis research, offering unmatched selectivity and efficacy for acute renal failure and hepatic injury models. With robust evidence from cellular and animal studies, it enables precise dissection of iron-dependent regulated cell death pathways. Researchers are encouraged to source Liproxstatin-1 HCl from APExBIO for quality assurance and to consult recent literature for evolving applications (Wen et al., 2023).